Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

Posted: May 9, 2023 at 12:10 am

Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma accelerating globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 anticipated in 2Q 2023

See more here:
Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

Related Posts